What is Thymalin used for in the source literature?

Thymalin is described as a calf-thymus-derived polypeptide complex associated with the Soviet and Russian peptide-bioregulator literature. The source reports regional medical use for immune-deficiency contexts and geroprotection claims, but it also notes that evidence outside that tradition is limited and that it is not FDA or EMA approved.

Is Thymalin a single peptide?

The source does not describe Thymalin as one defined amino-acid sequence. It characterizes it as a thymus extract containing short peptide fractions, with EW and KE named as identified active fractions.

How is Thymalin proposed to work?

The proposed action is broad immunomodulation and gene-regulatory activity rather than a single receptor target. Source material links short thymus-derived peptides to DNA or histone-associated binding, downstream changes in cytokines, heat-shock proteins, differentiation pathways, lymphocyte activity, and phagocytosis.

Is Thymalin FDA approved?

No. The source lists Thymalin as not FDA approved, while also stating that it is approved in Russia.

What side effects are reported?

The source lists generally good tolerability, rare allergic reactions, injection-site reactions, and rare flu-like symptoms. These are reported effects from the provided evidence and do not define an individual safety profile.

What dosing information was extracted?

The community-reported entry lists 10-20 mg daily for 5-10 days, with a 5-20 mg daily range and intramuscular administration. A research-literature row lists 10 mg daily for 10 days by intramuscular injection. These are evidence-extracted reports, not medical instructions.

Bioregulators Clinical Trials - human trials under way

Thymalin

Also known as: Thymic Factor, Thymus Extract

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Thymus-derived peptide complex researched for immune and aging-related biology

Status

Clinical Trials

Evidence level: human studies

Typical dose

10–20mg

Intramuscular injection

Researched for

Immune support, thymic function, longevity

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Not applicable - Emerging human evidence with important limitations

Use the tools

In plain language

Thymalin is described as a calf-thymus polypeptide complex in the Khavinson bioregulator tradition.
Source evidence reports approval in Russia and no FDA approval.
Extracted evidence status indicates human trials, while the trial-phase field conflicts by listing .
Reported research areas include immune support, thymic function, and longevity.
Extracted dosing reports include short intramuscular daily cycles, but these are not medical recommendations.

How it's thought to work

Thymalin is presented as a thymus-derived mixture with short identified fractions such as EW and KE. The proposed mechanism is immunomodulatory and gene-regulatory: source material links these peptides to interactions with DNA or histone-associated regions that may influence cytokine signaling, heat-shock protein expression, cellular differentiation, T- and B-lymphocyte function, and phagocytosis. Because the material is a complex extract, the evidence does not support reducing its action to one receptor or one molecular target.

What the research shows

Where the research stands

The supplied research summary places most Thymalin literature in Russian and Khavinson-associated research programs, spanning cell experiments, animal studies, observational work, and clinical reports. It cites reviews describing lymphocyte and immune-function findings, fewer acute respiratory disease observations in older groups, geroprotective claims, mortality observations in older subjects receiving thymus and pineal peptides, and a study of immune-status regulation in severe COVID-19 among older patients. The source also cautions that although some randomized or placebo-controlled data exist, studies are commonly small, regionally concentrated, and not replicated at a scale expected for major Western regulatory review.

What it shows

✓ Human studies

Emerging human evidence with important limitations

△ Limitations

Study protocols describe research and are not dosing recommendations.

Bottom line: Approved in Russia - Not FDA approved Not FDA Approved

Typical dosing

CommunityCommunity dataset

10–20 mg

daily for 5-10 days

5 mgfull range seen20 mg

Community reports describe short daily cycles for immune-support contexts within the Khavinson bioregulator tradition; this is not an independently validated dosing recommendation.

Research dosing

Study-specific protocolsHuman trials under way - protocols are study-specific

Doses observed in studies

10 mg daily for 10 days

Research Literature - Observed in studies

Study protocols describe research and are not dosing recommendations.

Duration: 10-day cycles, 1-2 times yearly
Administration: Intramuscular injection

Timing & administration

Best time to take

Morning

Once daily or as directed

Food recommendation

With or without food

Why this timing?

The source links morning timing to the idea that immune activity follows daily rhythms and may be more active during daytime hours.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well tolerated
Allergic reactions
Injection-site reactions
Flu-like symptoms

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Thymalin

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Thymalin

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows